Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00206128 · ClinicalTrials.gov registry record · Phase 3
Immediate Release (IR) to Sustained Release (SR) Switching Study: Study of Switching From IR Seroquel to SR Seroquel in Outpatients With Schizophrenia
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 454
- Enrollment target
NCT00206128 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 454 participants.
The verdict
NCT00206128, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 454 participants
- Enrollment target
Study Summary
The purpose of this study is to determine that the efficacy of the sustained release (SR) formulation of quetiapine (Seroquel) is not inferior to the immediate release (IR) formulation. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.
Interventions
- DRUG Seroquel SR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 454 participants |
| Start Date | 2004-11 |
| Est. Completion | 2006-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00206128
The ClinicalTrials.gov registry entry for NCT00206128 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 454 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Seroquel SR is the first listed.
NCT00206128 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00206128 about?
NCT00206128 is a clinical study titled "Immediate Release (IR) to Sustained Release (SR) Switching Study: Study of Switching From IR Seroquel to SR Seroquel in Outpatients With Schizophrenia". The purpose of this study is to determine that the efficacy of the sustained release (SR) formulation of quetiapine (Seroquel) is not inferior to the immediate release (IR) formulation. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR afte...
What is the current status of trial NCT00206128?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 454 participants. The study started on 2004-11. Estimated completion is 2006-02.
What interventions are being tested in trial NCT00206128?
The interventions under investigation include: Seroquel SR (DRUG).
Who is sponsoring clinical trial NCT00206128?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.